Aura Biosciences to Participate in Upcoming Investor Conferences

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • National University Receives 2023 Military Friendly® Gold Designation • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • AI-Powered Stylitics Launches Latest Platform with First-of-Its-Kind Automated Styling Technology for Retailers • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI • Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting • Philadelphia Works Names First Female Chief Operating Officer • 30+ Health Leaders Explore Strategies to Ease Hospital-to-Home Patient Transitions • Build community with shared future, create better world • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC, a partner of Veterans for Trump • Statement from the Chief Public Health Officer of Canada on World TB Day • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges • ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON , February 09 /Businesswire/ - Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:

SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.

Fireside Chat at 12:00 p.m. ET.
43^rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023.

Auditory & Ophthalmology Panel Discussion at 12:50 p.m. ET.

Live webcasts of the SVB fireside chat and Cowen panel discussion will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura has initiated activities for the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive bladder cancer (NMIBC). Aura is headquartered in Boston, MA.